• KHUJITH RAJUENI Poona College of Pharmacy, Bharati Vidyapeeth University
  • RUTUJA AMBEKAR Poona College of Pharmacy, Bharati Vidyapeeth University
  • HITENDRAPAL SOLANKI Poona College of Pharmacy, Bharati Vidyapeeth University
  • ABDULRAHAMAN ABUBAKAR MOMIN Department of Biochemistry Bharati Vidyapeeth (DTU) Medical College, Pune India
  • SUNITA PAWAR Department of Clinical Pharmacy, Pharm D, Poona College of Pharmacy, Bharati Vidyapeeth University



Covid-19, Type 2 diabetes mellitus, Post-covid, Uncontrolled diabetes mellitus, Newly diagnosed diabetes mellitus, Steroids, Prednisolone


Objective: Novel COVID-19 virus is extensively being studied for its long-term effects. A predominant trend of development of Diabetes Mellitus (DM) in Covid-19 patients is being observed, and hence further relation is explored in this study.

Methods: This is an observational inductive retrospective study conducted for four months in a tertiary care hospital. The study included subjects who recovered from COVID-19 and were treated post-COVID-19 in the hospital. The subjects who had stable glucose counts were excluded. The data obtained from the medical record department encompassed demographic details and clinical data of the patient. The data were tabulated, and observations were reported using descriptive analysis.

Results: Among 5632 admitted patients for COVID-19, 694 came for follow-up. 105 patients were re-admitted, but 11 had newly developed DM, and 14 observed uncontrolled DM managed by medical attention. The reported incidence rate in Newly-Diagnosed DM was 0.195%, and the person above 41 y was at greater risk. Similarly, the incidence rate in Uncontrolled-DM was 13.33%, and persons above 47 y were at greater risk. It was found that both these categories of patients had comorbidities, and the development of this was seen between the 25th-40th day. In both cases, males were more prone than females.

Conclusion: The study reports a bi-directional relationship between Covid-19 and DM. The use of steroids may have stepped-up this relationship. Cautious use of steroids, changes in the hospital formulary, and further quantitative clinical investigations are primary recommendations that may prevent such episodes.


Download data is not yet available.

Author Biographies

KHUJITH RAJUENI, Poona College of Pharmacy, Bharati Vidyapeeth University

Dr. (Mr.) Khujith Rajueni (Intern)

Pharm. D (Post Baccalaureate) (pursuing) | B. Pharm



  • Currently pursuing Pharm. D, post-baccalaureate and therefore on the march to the final year, Bharati Vidyapeeth’s Poona College of Pharmacy – 06/18 – Present
  • Bachelors of Pharmacy, Vivekananda Education Society’s College of Pharmacy – 06/14 – 05/18




  • Intern research pharmacist at Wanbury Pvt. Ltd.; assisted in the research of Lamivudine, qualitative analysis of Lamivudine. – 06/19 – 03/20
  • Intern Manufacturing pharmacist at Wanbury Pvt. Ltd.; simultaneous service at Qualitative analysis for two weeks – 05/17 – 06/17



  • Currently also a Faculty/ Lecturer at Trinity College of Pharmacy, Pune. – 02/21 – Present
  • Research Intern for rare disease project at Indian Institute of Science, Bengaluru – 05/21 - Present



  • Communication initiated towards research on COVID – 19 and diabetes Mellitus under Dr Sunita Pawar, PhD.
  • Communication initiated towards publication on research conducted on Hormone Replacement Therapy - Practices under Dr.Abhishek Royal, WHO Scholar
  • Ongoing research on research conducted on Hormone Replacement Therapy – Challenges and Barriers under Dr Abhishek Royal, WHO Scholar




  • Council Member of Society of Pharmaceutical Education and Research – 11/19 – Present
  • Member of International Society for Pharmacoeconomics and Outcomes Research – 07/19 – Present
  • Council Member of Literature Society at Poona College of Pharmacy – 06/19 – Present
  • Assistant Magazine Secretary of Vivekananda Education Society’s College of Pharmacy – 06/15 – 06/16
  • Member of the Student’s Council of Vivekananda Education Society’s College of Pharmacy - 06/15 – 06/16




  • Runner Up at Literature Society of Poona College of Pharmacy for Blogathon
  • Runner Up at Indian Pharmaceutical Association – Student Forum’s 52nd Pharmacy Week Debate Competition.
  • Winner at In-house debate competition at Vivekananda Education Society’s College of Pharmacy.
  • Winner at In-house Chess competition at Vivekananda Education Society’s College of Pharmacy



  • National Forum for Pharmacy Student’s Forth Practicum.
  • Research Revanderous, Dr Vaibhav Kumar, Publication Consultant
  • ISPOR event on Platelets and Dialysis
  • Journal Club’s Publication and its need.




  • Co-organiser and host of an event viz. ’Genero - Discover sensitivity’ held by ISPOR in collaboration with Bharati Vidyapeeth’s deemed to be University. - 02/21
  • Currently learning German as a foreign language; completed up to A2
  • Worked at a Non-Government Organisation viz. ‘Hamsafar Trust’ for 6 months – 06/15 – 12/15


RUTUJA AMBEKAR, Poona College of Pharmacy, Bharati Vidyapeeth University



     Pande lane, Near Gadhichya Ganapati, Dindori, Tal-dindori Dist-Nashik

 8605597115, 8605467618        


2019 – present Doctor of Pharmacy, Bharati Vidyapeeth Deemed to be University, Pune

2015 – 2019    Bachelor of pharmacy, Savitribai Phule Pune University

2014 – 2015    H.S.C, Maharashtra state Board

2012 – 2013    S.S.C, Maharashtra state Board


Technical Expertise:

Clinical Research, Clinical Pharmacy, Pharmacovigilance,

MS Office:

MS Word, MS Excel, MS PowerPoint

Soft Skills

Team leasion, Soft Communication, Active Listener, Problem solving, Hard Working




ISPOR-THE PROFESSIONAL SOCIETY FOR HEALTH ECONOMICS AND OUTCOMES RESEARCH STUDENTS CHAPTER (2019-2021) -I have volunteered in various activities under this organization.


INDIA PHARMACEUTICAL ASSOCIATION-STUDENT CHAPTER (PUNE) 2019-2020- I have volunteered in various activities under this organization.


Community activities:

I have Volunteered at the Oral Cancer screening and Awareness Avoid Tobacco Camp organized by Poona college of pharmacy at kothrud.



Work as an Intern at the clinical trial site at H.C.G Curie Manvata Hospital – June 2018


Good Clinical Practices (NIDA Clinical Trials Network)

Introduction to Pharmacovigilance (Uppsala Monitoring Centre)

Signal Detection and Causality Assessment (Uppsala Monitoring Centre)

Statistical reasoning and algorithms in pharmacovigilance (Uppsala Monitoring Centre)

 Antimicrobial Stewardship: A competency-based approach (World Health Organization)

Identifying, recording, reporting and analysis of priority diseases, conditions and events (World Health Organization)

Management of Diabetic Macular Edema (DME) (International Federation of Diabetes)

Maharashtra State Certification in Information Technology(MS-CIT)



Vaccine safety monitoring and Reporting Series including Hands-on Training

Attend state-level conferences entitled “Alternatives to preclinical studies and recent

Approaches to in treating chronic disease.”

Attend State Level Conferences entitled “Drug Discovery and Recent Development.”


Personal Information

Full Name: Ambekar Rutuja Kailas

Gender: Female

Date of Birth: 08 April 1997

Language Known: English, Hindi, Marathi

Permanent Address:  Pande lane, Near Gadhichya Ganapati, Dindori, Tal-dindori Dist.-Nashik

Hobbies: Dancing, drawing, Traveling



I do hereby declare that the above information is true & to the best of my knowledge.

HITENDRAPAL SOLANKI, Poona College of Pharmacy, Bharati Vidyapeeth University



  • Pharm D
  • Pursuing from Poona college of Pharmacy, Bharati Vidyapeeth deemed to be University, Pune
  • Pharmacy (2019) with aggregate 70%
  • N.Institute of Pharmacy, Rajasthan University of Heath and Sciences Jaipur, Rajasthan
  • Higher secondary certificate (2015) with 56%
  • Vikas Jr. College of Science, Commerce and Arts, Maharashtra
  • Senior Secondary Certificate (2013) with 73%
  • Vidya Mandir High School, Mumbai Maharashtra




  • ISPOR-THE PROFESSIONAL SOCIETY FOR HEALTH ECONOMICS AND OUTCOMES RESEARCH STUDENTS CHAPTER (2019-2021) -I have volunteered various activities under this organization.
  • Community activities: Attended various blood donation camp since 2019 through different organizations.
  • Work experience: I have been working as a Pharmacist in retail Pharmacy since 2 years


Skills and Ability

  • Well versed with Microsoft Office,team player, Growth mindset, Hardworking.


Ren H, Yang Y, Wang F, Yan Y, Shi X, Dong K, et al. Association of the insulin resistance marker TyG index with the severity and mortality of COVID-19. Cardiovascular Diabetology 2020;19:58.

Rubino F, Amiel SA, Zimmet P, Alberti G, Bornstein S, Eckel RH, et al. New-onset diabetes in covid-19. New England J Med 2020;383:789–90.

Suastika K, Dwipayana P, Siswadi M, Tuty RA. Age is an Important risk factor for type 2 diabetes mellitus and cardiovascular diseases. In: Glucose Tolerance. InTech; 2012.

Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection; 2020. Available from: [Last accessed on 10 May 2021]

Bouhanick B, Cracowski JL, Faillie JL. Diabetes and COVID-19. Therapies 2020;75:327–33.

Pal R, Bhadada SK. COVID-19 and diabetes mellitus: an unholy interaction of two pandemics. Diabetes Metabolic Syndrome: Clin Res Rev 2020;14:513–7.

Wang W, Lu J, Gu W, Zhang Y, Liu J, Ning G. Care for diabetes with COVID-19:Advice from China. Vol. 12. Journal of Diabetes. John Wiley and Sons Inc; 2020. p. 417–9.

Peric S, Stulnig TM. Diabetes and COVID-19: Disease-management-people. Wiener Klinische Wochenschrift 2020;132:356–61.

P DJ, Kumar N DP, A VM, A R. Alterations of lipid levels may induce the insulin resistance in type two diabetes mellitus: a systemic review. Asian J Pharm Clinical Res 2020;27:9–20.

Lim S, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Vol. 17. Nature Reviews Endocrinology. Nature Research; 2021. p. 11–30.

Umakanthan S, Sahu P, Ranade AV, Bukelo MM, Rao JS, Abrahao Machado LF, et al. Origin, transmission, diagnosis and management of coronavirus disease 2019 [COVID-19]. Vol. 96, Postgraduate Medical Journal. BMJ Publishing Group; 2020. p. 753–8.

Erener S. Diabetes, infection risk, and COVID-19. Vol. 39. Molecular Metabolism. Elsevier GmbH; 2020.

Qadrie ZL, Wani Sud, Gautam SP, Khan MKA. Outbreak, epidemiology, therapeutics and prevention of coronavirus disease-2019: a review. Int J Curr Pharm Res 2020;323:1824-36.

Bansal M, Walia MK. COVID 19-an overview on epidemiology, symptoms, prevention, management, treatmen, t and role of health workers. Int J Appl Pharm 2020;12:36–41.

Hartmann Boyce J, Morris E, Goyder C, Kinton J, Perring J, Nunan D, et al. Diabetes and COVID-19: Risks, management, and learnings from other national disasters. Diabetes Care 2020;43:1695–703.

Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes/Metab Res Rev 2020;36. DOI:10.1002/dmrr.3319

World Health Organization, International Diabetes Federation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation. 46; 2006.

Demanuele F, Hines RM, Walter JR. CPP for family practice use. Six of them are from community practices and ten from teaching units. The Cumulative Patient Profile in Family Practice; 1977.

The Lancet. India’s COVID-19 emergency. Lancet [London, England] [Internet]; 2021;397:1683. Available from: [Last accessed on 10 May 2021]

Mishra SK, Tripathi T. One year update on the COVID-19 pandemic: Where are we now? Vol. 214. Acta Tropica. Elsevier B. V.; 2021.

Nerhagen S, Moberg HL, Boge GS, Glanemann B. Prednisolone-induced diabetes mellitus in the cat: a historical cohort. J Feline Med Surgery 2021;23:175–80.

Sittig KR, Laageide LG, Akhtar Z, Wall GC, Kumar SC. Cutaneous mucormycosis in a chronic lymphocytic leukemia patient on ibrutinib. IDCases; 2021. p. 24.

Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A, del Prato S. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Vol. 8. The Lancet Diabetes and Endocrinology. Lancet Publishing Group; 2020. p. 782–92.

Perrin R, Riste L, Hann M, Walther A, Mukherjee A, Heald A. Into the looking glass: Post-viral syndrome post-COVID-19. Vol. 144. Medical Hypotheses. Churchill Livingstone; 2020.

Misra P, Upadhyay RP, Misra A, Anand K. A review of the epidemiology of diabetes in rural India. Diabetes Res Clin Practice 2011;92:303–11.

Knapp S. Diabetes and infection: is there a link?-a mini-review. Gerontology 2013;59:99–104.

Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Inf 2020;26:1622–9.

Suh S, Park MK. Glucocorticoid-induced diabetes mellitus: an important but overlooked problem. Endocrinol Metab 2017;32:180–9.

Shah M, Adel MM, Tahsin B, Guerra Y, Fogelfeld L. Effect of short-term prednisone on beta-cell function in subjects with type 2 diabetes mellitus and healthy subjects. PLoS One 2020;15:e0231190.

Gao F, Zheng KI, Wang XB, Sun QF, Pan KH, Wang TY, et al. Obesity is a risk factor for greater COVID-19 severity. Vol. 43. Diabetes Care. American Diabetes Association Inc; 2020. p. E72–4.

Zhou Y, Chi J, Lv W, Wang Y. Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 [Covid-19]. Vol. 37. Diabetes/Metabolism Research and Reviews. John Wiley and Sons Ltd; 2021.

Heindel JJ, Blumberg B, Cave M, Machtinger R, Mantovani A, Mendez MA, et al. Metabolism disrupting chemicals and metabolic disorders. Reproductive Toxicol 2017;68:3–33.

Rao KN, Patil N, Vidyasagar S, Manjunath Holla A. Clinical and biochemical profile of steroid-induced diabetes. Asian J Pharm Clin Res 2016;9:262-6.

Pugliese G, Vitale M, Resi V, Orsi E. Is diabetes mellitus a risk factor for Corona VIrus Disease 19 [COVID-19]? Acta Diabetol Springer Verlag Italia 2020;57:1275–85.

Mehta S, Pandey A. Rhino-orbital mucormycosis associated with COVID-19. Cureus 2020;12:e10726.



How to Cite

RAJUENI, K., R. AMBEKAR, H. SOLANKI, A. A. MOMIN, and S. PAWAR. “ASSESSMENT OF THE POSSIBLE CAUSES OF DIABETES MELLITUS DEVELOPED IN PATIENTS POST COVID-19 TREATMENT IN A TERTIARY CARE HOSPITAL”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 13, no. 9, Sept. 2021, pp. 11-15, doi:10.22159/ijpps.2021v13i9.42508.



Original Article(s)